|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2-3
|
|
pubmed:dateCreated |
2007-5-21
|
|
pubmed:abstractText |
To obtain preliminary evidence on the safety and efficacy of high dose nicotine patch therapy among smokeless tobacco (ST) users who consume > or =3 cans of ST per week, we conducted a randomized, placebo-controlled clinical trial with 42 ST users randomized to nicotine patch doses of 21, 42, and 63 mg/day or placebo. Serum nicotine concentrations were measured during ad libitum ST use and nicotine replacement therapy, and percentages of nicotine replacement were calculated. We observed substantial inter-subject variability in nicotine concentrations with ad lib ST use. The mean percentage replacement of ad lib ST use serum nicotine concentrations approximated 100% with the 42 mg/day patch dose (mean+/-S.D., 98.4%+/-45%). Dosing with the 21 mg/day nicotine patch was associated with mean "under-replacement" (53.2%+/-17.1%), and the 63 mg/day nicotine was associated with mean "over-replacement" (159.2%+/-121.9%). We observed symptoms of nausea consistent with nicotine toxicity in two subjects in the 63 mg/day group while no subjects in the 42 mg/day reported these symptoms. We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use > or =3 cans/week.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-10609971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-10780124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-12194923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-12215235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-12519537,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-12728167,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-14660766,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-14732423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-15182890,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-15953977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-16040726,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-2742246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-3391001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-7563559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-8568016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-8907095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17300878-9650539
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0376-8716
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
223-6
|
|
pubmed:dateRevised |
2011-2-10
|
|
pubmed:meshHeading |
pubmed-meshheading:17300878-Administration, Cutaneous,
pubmed-meshheading:17300878-Adult,
pubmed-meshheading:17300878-Dose-Response Relationship, Drug,
pubmed-meshheading:17300878-Humans,
pubmed-meshheading:17300878-Male,
pubmed-meshheading:17300878-Middle Aged,
pubmed-meshheading:17300878-Nicotine,
pubmed-meshheading:17300878-Tobacco, Smokeless,
pubmed-meshheading:17300878-Tobacco Use Disorder,
pubmed-meshheading:17300878-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Nicotine percentage replacement among smokeless tobacco users with nicotine patch.
|
|
pubmed:affiliation |
Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA. ebbert.jon@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
